BRAF and neoplasm: Their anti-tumor efficacy was also validated in a xenograft model.412 Furthermore, this group developed a new degrader, MS15, based on an AKT allosteric inhibitor, which also demonstrates AKT degradation and anti-proliferative activity in cancer cells with KRAS/BRAF mutations, offering a new approach to overcoming MS21 resistance.412